This is a working overview of cyclic heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-18. Anything still debated is marked as such rather than presented as settled.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Bophuthatswana (, lit. 'gathering of the Tswana people'), officially the Republic of Bophuthatswana (Tswana: Repaboleki ya Bophuthatswana; Afrikaans: Republiek van Bophuthatswana), colloquially referred to as the Bop and by outsiders as Jigsawland (In reference to its enclave-ridden borders) was a Bantustan (also known as "Homeland", an area set aside for members of a specific ethnicity) that was declared (nominally) independent by the apartheid regime of South Africa in 1977. However, like the other Bantustans of Ciskei, Transkei and Venda, its independence was not recognized by any country other than South Africa. Bophuthatswana was the second Bantustan to be declared an independent state by the Apartheid government, after Transkei. Its territory constituted a scattered patchwork of enclaves spread across what was then Cape Province, Orange Free State and Transvaal. Its seat of government was Mmabatho, which is now a suburb of Mahikeng. On 27 April 1994, it was reintegrated into South Africa with the coming into force of the country's interim constitution. Its territory was distributed between the new provinces of the Free State, Gauteng, Mpumalanga and North West Province.
In two minor league seasons from 1989 to 1990, he had managed six home runs in 932 at bats–a ratio of 155 at bats per home run (AB/HR). With 15 home runs in his first year in Houston, that average shrunk to 36.9. He also exhibited extraordinary plate discipline for a rookie: while ranking tenth in the league in walks with 75, his OBP placed fifth at .387. Of the power surge, commented Bagwell to hitting coach Rudy Jaramillo, "That's awesome", to which he reacted, "Awesome? We can get more out of you than that." By altering an approach to contact the pitch with topspin as he did when he arriving to Houston, Jaramillo taught Bagwell to hit with backspin, resulting in a soaring trajectory rather than nose diving. He also habituated Bagwell to manipulate the count, waiting for a pitch to drive instead of indiscriminately swinging at any pitch that appeared to be a strike. Accounted Bagwell of the newfound advantage, "I didn't hit many home runs in the minor leagues, but when I hit one, when I got backspin on it, it went a long way." Although firmly established as the Astros' first baseman from Opening Day in 1991, Bagwell remarked years later that transitioning from third base was not automatic. First basemen approach fielding plays from their right side, which is opposite to playing third base. He recounted one conversation that occurred during an Astros pitching change in a game against St. Louis. Shortstop Ozzie Smith was on first and asked Bagwell, "How's it going?" Bagwell responded, "I'm really struggling with my backhand." Smith replied, "Well, here's what you do.
Plecanatide, sold under the brand name Trulance, is a medication for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation. It is available in India under the brand name Plectide (OQM Div, MSN Laboratories, India). Plecanatide is an agonist of guanylate cyclase-C. Plecanatide increases intestinal transit and fluid through a buildup of cGMP.
Sources: en.wikipedia.org
In an experiment by Hanson et al. that was published in 2006, the amount of harmful reactive oxygen species (ROS) was measured in untreated and in sunscreen treated skin. In the first 20 minutes, the film of sunscreen had a protective effect and the number of ROS species was smaller. After 60 minutes, however, the amount of absorbed sunscreen was so high that the amount of ROS was higher in the sunscreen-treated skin than in the untreated skin. The study indicates that sunscreen must be reapplied within 2 hours in order to prevent UV light from penetrating to sunscreen-infused live skin cells.
== Reactions == Fraser stated in July 2023 that over five hundred athletes had contacted him asking for more information. In August, D'Souza said that he had 500 "sleeper athletes" who are "breaking world records in their basement and sending us videos of it" ready for competition. In February 2024, he said that thousands of athletes interested in participating had contacted him. CNN reported in October 2023 that no athletes had publicly committed to the event; however, by early 2026, several high-profile international competitors, including former world champion James Magnussen and British swimmer Emily Barclay, had expressed interest or confirmed their participation.
X-ray crystallography is one of the more efficient and important methods for attempting to decipher the three dimensional configuration of a folded protein. To be able to conduct X-ray crystallography, the protein under investigation must be located inside a crystal lattice. To place a protein inside a crystal lattice, one must have a suitable solvent for crystallization, obtain a pure protein at supersaturated levels in solution, and precipitate the crystals in solution. Once a protein is crystallized, X-ray beams can be concentrated through the crystal lattice which would diffract the beams or shoot them outwards in various directions. These exiting beams are correlated to the specific three-dimensional configuration of the protein enclosed within. The X-rays specifically interact with the electron clouds surrounding the individual atoms within the protein crystal lattice and produce a discernible diffraction pattern. Only by relating the electron density clouds with the amplitude of the X-rays can this pattern be read and lead to assumptions of the phases or phase angles involved that complicate this method. Without the relation established through a mathematical basis known as Fourier transform, the "phase problem" would render predicting the diffraction patterns very difficult. Emerging methods like multiple isomorphous replacement use the presence of a heavy metal ion to diffract the X-rays into a more predictable manner, reducing the number of variables involved and resolving the phase problem.
Sources: en.wikipedia.org
This process has also been observed in simulations of transthyretin and implicated as occurring naturally in certain protein families by examination of their dihedral angle conformations in crystal structures. It is suggested that alpha-sheet folds into multi-strand solenoids.
== Menu == Culver's menu consists of butter burgers, chicken sandwiches, chicken tenders, fish, salads, soup, onion rings, french fries, cheese curds, and corn dogs. For dessert, the restaurant offers its frozen custard, served in either a dish, cone, or blended into a concrete mixer, malt, or shake. The company released an April Fools' joke in 2021 showing a large fried cheese curd in a burger bun, naming it the CurderBurger. Soon after the post was made, a change.org petition was created to make the burger a reality, gathering over 600 signatures. In celebration of National Cheese Curd Day on October 15 that year, the CurderBurger debuted, consisting of a large cheese curd on top of a burger patty. Each location only got a limited number of cheese curd patties, and all Madison, Wisconsin restaurants sold out before noon.
== Innovation == The Global Innovation Index 2024, by World Intellectual Property Organization: Thailand ranked 41 of 133 nations. The Global Innovation Index 2019 ranked Thailand 43 of 129 nations. Other ASEAN nations ranked were: Singapore, 8; Malaysia, 35; Vietnam, 42; Philippines, 54; Brunei, 71; Indonesia, 85; Cambodia, 98. The Bloomberg Innovation Index, 2018 ranked Thailand 45 of 50 nations (1=most innovative; 50=less innovative). Singapore was ranked 3 and Malaysia number 26. The Bloomberg Innovation Index, 2017 ranked Thailand 44 of 50 nations (1=most innovative; 50=less innovative), a rise from 47 in the 2016 ranking. Other ASEAN nations ranked were Singapore, 6 of 50 and Malaysia, 23 of 50. The Global Innovation Index 2015 ranked Thailand 55 of 141 (1=best; 141=worst) countries.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.